GSK Acquires RAPT Therapeutics in Major Food Allergy Deal
GSK acquires RAPT Therapeutics for up to $2.2bn, gaining rights to a Phase IIb food allergy drug candidate. The deal marks one of the first major pharma acquisitions of 2026.
Topic
Latest reporting and analysis tagged with GSK.
GSK acquires RAPT Therapeutics for up to $2.2bn, gaining rights to a Phase IIb food allergy drug candidate. The deal marks one of the first major pharma acquisitions of 2026.